At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
MM-121 +2 moredrug
Likely dose
Irinotecan 180 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers
In Brief
A Phase 1 clinical trial evaluating MM-121, Irinotecan, and 1 other intervention for Colorectal Cancer and 4 related conditions. Completed, enrolled 48 participants across 4 sites.
Detailed Summary
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Other Tumors With EGFR Dependence
CountriesUnited States
CollaboratorsSanofi
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedOct 2011
Primary CompletionNov 2013
Study CompletionJun 2014
TodayJul 2026
First PostedOct 13, 2011
Enrollment StartOct 1, 2011
Primary CompletionNov 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.7 years ago
Interventions
MM-121drug
escalating doses MM-121 IV QW
Irinotecandrug
180 mg/m2 IV Q2W
Cetuximabdrug
escalating doses cetuximab IV QW